VIDEO: Adjuvant atezolizumab provides DFS benefit in patients with resected NSCLC

ByRoy Herbst, MD, PhD

ByMarley V. Ghizzone

In this video, Roy Herbst, MD, PhD, spoke with Healio about the practice changing IMpower010 trial presented at the virtual ASCO Annual Meeting.

“This has been very exciting to see that the first of what will be many adjuvant trials has, at least in part, hit its endpoint,” Herbst, associate cancer center director for translational research at Yale Cancer Center, said.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview; Wakelee HA, et al. Abstract 8500. Scheduled for presentation at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Disclosures: Herbst reports serving in a leadership role with Junshi Pharmaceuticals; serving in a consulting or advisory role for AbbVie, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, eFFECTOR Therapeutics, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, I-Mab, Immunocore, Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire, Spectrum Pharmaceuticals, STCube Pharmaceuticals Inc., Symphogen, Takeda, TESARO, Tocagen, WindMIL and Xencor; and receiving research funding from AstraZeneca, Genentech/Roche, Lilly and Merck.

Take Homes in Lung Cancer

Read more

VIDEO: Adjuvant atezolizumab provides DFS benefit in patients with resected NSCLC

Related Content